<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04261166</url>
  </required_header>
  <id_info>
    <org_study_id>BOL-PK-ST-02</org_study_id>
    <nct_id>NCT04261166</nct_id>
  </id_info>
  <brief_title>The Aim of This Study is to Evaluate the Safety and PK of BOL-PK-ST-02A, BOL-PK-ST-02 and BOL-PK-ST-02C Drops and a New Sublingual Tablet Formulation of BOL-PK-ST-02F, BOL-PK-ST-02D, BOL-PK-ST-02E</brief_title>
  <official_title>A Phase I Open-label Study to Assess the Single-dose Pharmacokinetics and Safety of Sublingual Administration of Tablets and Medicated Drops</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Breath of Life International Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Breath of Life International Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, single-dose, healthy volunteer phase 1 study after overnight
      fasting designed to study the safety and PK of medicated drops and tablet formulation for
      sublingual administration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">April 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile - Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Baseline (up to 15 minutes prior to dosing), 10 minutes , 20 minutes, 30 minutes and 45 minutes and 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours,4 hours ,6 hours, 8 hours, 10 hours and 12 hours post dosing</time_frame>
    <description>Blood will be collected for PK testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile - time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>Baseline (up to 15 minutes prior to dosing), 10 minutes , 20 minutes, 30 minutes and 45 minutes and 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours,4 hours ,6 hours, 8 hours, 10 hours and 12 hours post dosing</time_frame>
    <description>Blood will be collected for PK testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile - apparent terminal exponential half-life (T1/2)</measure>
    <time_frame>Baseline (up to 15 minutes prior to dosing), 10 minutes , 20 minutes, 30 minutes and 45 minutes and 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours,4 hours ,6 hours, 8 hours, 10 hours and 12 hours post dosing</time_frame>
    <description>Blood will be collected for PK testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile - Area Under the Curve (AUC)</measure>
    <time_frame>Baseline (up to 15 minutes prior to dosing), 10 minutes , 20 minutes, 30 minutes and 45 minutes and 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours,4 hours ,6 hours, 8 hours, 10 hours and 12 hours post dosing</time_frame>
    <description>Blood will be collected for PK testing</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BOL-PK-ST-02F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOL-PK-ST-02E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B3 is BOL-PK-ST-02D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOL-PK-ST-02A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOL-PK-ST-02C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOL-PK-ST-02B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-PK-ST-02A</intervention_name>
    <description>drops</description>
    <arm_group_label>BOL-PK-ST-02A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-PK-ST-02C</intervention_name>
    <description>drops</description>
    <arm_group_label>BOL-PK-ST-02C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-PK-ST-02B</intervention_name>
    <description>drops</description>
    <arm_group_label>BOL-PK-ST-02B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-PK-ST-02F</intervention_name>
    <description>Sublingual tablets</description>
    <arm_group_label>BOL-PK-ST-02F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-PK-ST-02E</intervention_name>
    <description>Sublingual tablets</description>
    <arm_group_label>BOL-PK-ST-02E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-PK-ST-02D</intervention_name>
    <description>Sublingual tablets</description>
    <arm_group_label>B3 is BOL-PK-ST-02D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy, male or female, between 18 and 45 years of age (inclusive).

          2. Body mass index (BMI) between 20-30 kg/m2 (both inclusive)

          3. No recent cannabis usage

          4. Normal rage hepatic functions

          5. No electrolytes abnormalities

          6. Vital signs at screening (after five minutes resting measured in the supine position)
             within the following ranges:

               1. Body temperature between 35.0 to 37.5 Â°C

               2. Systolic blood pressure, 90 to 150 mmHg*

               3. Diastolic blood pressure, 60 to 90 mmHg*

               4. Pulse rate, 50 to 90 beats per minute*.

               5. *Blood pressure and pulse rate will be taken again in a standing position. After
                  two minutes standing, there shall be no more than a 20 mmHg drop in systolic or
                  10 mmHg drop in diastolic blood pressure, associated with clinical manifestation
                  of postural hypotension).

        Exclusion Criteria:

          1. Blood donation within 90 days

          2. History of significant cardiovascular, pulmonary, hepatic, renal, hematologic,
             gastroenterology, endocrine, immunology, dermatologic, neurologic or psychiatric
             disorders

          3. Subjects with a history of alcohol, drug abuse, chronic cannabis use within 2 years of
             study

          4. Pregnant women

          5. Subjects who used any prescription or OTC medication in the past 14 days with the
             exception of paracetamol or ibuprofen.

          6. Sexually active males whose partner is of childbearing potential who do not agree to
             practice two highly effective methods of birth control or remain abstinent during the
             study and for three months after the last dose of IMP. Sexually active females of
             childbearing potential who do not agree to practice two highly effective methods of
             birth control or remain abstinent during the study and for three months after the last
             dose of IMP

          7. Pregnant, lactating or planning pregnancy during the course of the study and for three
             months thereafter.

          8. Subjects who had postural drop of &gt; 20 mmHg in systolic blood pressure at screening

          9. Patients with heart failure,

         10. Subjects with a history of psychotic state in the past or anxiety disorder,

         11. Subjects less than 30 y with a history of psychiatric disease in a first-degree family
             member.

         12. Subjects with a history of addiction or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ziv Medical Center</name>
      <address>
        <city>Zefat</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahien Radi, M.D.</last_name>
      <phone>+972508434197</phone>
      <email>shahien.r@iv.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

